C
andida bloodstream infections (BSIs) and other forms of invasive candidiasis are the most common invasive fungal infections among hospitalized patients (1) . In the United States, infections resulting from Candida BSI are currently the fourth leading cause of nosocomial BSIs among hospitalized patients and third among intensive care unit (ICU) patients (2) . Invasive Candida infections are an increasingly problematic in ICU patients as a result of the high crude mortality, ranging from 35% to 67% (2-7). Additionally, invasive candidiasis is also associated with significant cost and healthcare use (4, 8 -13) . The increased length of stay in the hospital and the ICU are major contributors to the economic burden of Candida BSI with estimated cost associated with an episode of candidemia between $25,000 and $55,000 (7) (8) (9) (10) 14) .
Fluconazole remains an effective systemic antifungal agent for treatment for Candida BSI (15) and patients with Candida BSI appear to benefit from early fluconazole therapy (16) . However, the 2009 Infectious Disease Society of America (IDSA) treatment guidelines favor the use of an echinocandin for primary therapy of candidemia in patients who are moderately ill to severely ill and recommend fluconazole for patients who are less critically ill (17) , in part based on the results of recent clinical trials of echinocandins in patients with candidemia and invasive candidiasis (18 -21) .
Understanding the current epidemiology of Candida BSI in critically ill patients may impact the choice of initial therapy. Significant regional and geographic differences exist in the incidence of the different Candida species (1-4, 6, 22-24 count for the approximately half of all Candida BSIs. Candida glabrata is generally the second most commonly isolated pathogen in North America (1, 2, (23) (24) (25) but occurs less frequently in other regions (3, 4, 6, 22, 23) .
The Extended Prevalence of Infection in Intensive Care study (EPIC II) was conducted to provide an up-to-date picture of the extent and patterns of infection in ICUs throughout the world (26) . We report the prevalence, epidemiology, treatment choices, and outcomes of Candida BSI in a worldwide sample of ICU patients. Also, patients with Candida BSIs were compared with patients with bacterial BSI and combined BSIs.
MATERIALS AND METHODS
Patient Selection. The EPIC II study was previously reported in detail (26) . ICUs were invited to participate in a 1-day, prospective, multicenter point prevalence study of infection. In brief, demographic, physiological, pathogen-related, and therapeutic data were collected from all patients in a participating ICUs between midnight on May 7 and midnight on May 8, 2007 . Simplified Acute Physiology Score II (27) and Sequential Organ Failure Assessment (28) scores were calculated for the study day. Data were recorded using preprinted case report forms. Participating ICUs were asked to provide patient follow-up until hospital discharge or for 60 days (until July 9, 2007), and ICU and hospital outcomes were recorded. The index study day was used to calculate pre-and postobservation time related to hospital and ICU length of stay and survival. Data were not monitored; however, centers with missing data were contacted regularly in an attempt to obtain complete data, but any data still missing at closure of the database were simply noted as absent.
Infection was defined according to the definitions of the International Sepsis Forum (29) and adjudicated by the attending physician. Participating sites classified patients as infected on the day of the study. All BSIs, Candida and bacterial, identified in the EPIC II database and deemed clinical infections by the participating sites were included in this analysis. Patients were grouped as Candida, Gram-positive, Gram-negative, and mixed Candida/bacterial BSI. Candida cultures were recorded as either Candida albicans or C. non-albicans.
For the purposes of analysis, the EPIC II steering committee divided the world into seven geographical regions: North America, Central and South America, Western Europe, Eastern Europe, Asia, Oceania, and Africa.
Participation in the EPIC II study was entirely voluntary, and the study was not funded. For the original EPIC II protocol, local ethical committee approval at each participating center was expedited or waived owing to the purely observational nature of the study.
Statistical Analyses. All data were analyzed in the Department of Intensive Care of the University of Brussels, Brussels, Belgium, in collaboration with the University of Jena, Jena, Germany. Statistical analyses were performed using SPSS for windows version 13.0 (SPSS Inc, Chicago, IL). Difference testing between groups was performed using analysis of variance, Kruskal-Wallis, Student's t test, MannWhitney test, chi square test, and Fisher's exact test as appropriate. All statistics were two-tailed and a p Ͻ .05 was considered to be statistically significant. A Bonferroni correction was made for multiple comparisons. Kaplan-Meier analysis between groups was used to compare survival to ICU and hospital discharge.
RESULTS

Characteristics of the Study Group.
The complete EPIC II study and patient characteristics are described (26) . In brief, EPIC II recruited 1265 ICUs in 76 countries. On the study day, 14,414 adult patients were in one of the participating ICUs. A total of 7330 (51%) was considered to be infected on the day of the study. Ninety-nine patients had Candida BSIs, resulting in a prevalence of 6.87 per 1000 ICU patients. Of these Candida BSIs, 61 patients were without other known BSI. Gram-positive BSIs occurred in 420 patients and Gram-negative BSIs in 264 patients. Thirty-eight patients had both Candida BSIs and bacterial BSIs.
Candida Species. C. albicans was the predominant species, accounting for approximately 70% of isolates (Table 1) . Latin America had the highest rate of non-albicans Candida species at 43%, although differences in species' prevalence by region were not significant. Participating ICUs in Africa did not report any Candida BSI.
Therapy. Fluconazole monotherapy was the predominant antifungal treatment; however, it is used in only Ͻ40% of patients with Candida BSIs (Table 2) . Echinocandins and amphotericin-based products were prescribed as monotherapy in 16.2% and 12.4% of patients with Candida BSIs, respectively. Combination therapy was used in 10.1% of patients. No obvious regional difference in prescribing practice is evident (Table 2 ). Using fluconazole therapy as the reference group, no significant difference was noted in demographic or severity of illness variables between patients grouped by therapy (Table 3). Choice of antifungal agent did not impact ICU or hospital survival or length of stay.
Comparison of Candida BSIs With Other BSIs. Demographic characteristics and outcomes of patients with BSIs are displayed in Table 4 . Compared with other BSIs, patients with candidemia were more frequently being treated for solid tumors (p Ͻ .05). Candidemia patients, compared with patients grouped as Gram-positive, Gram-negative, or mixed BSIs, also had a trend toward being in the ICU longer before the study day. The average number of days in the ICU before study day for the most common species of BSIs are displayed in Figure 1 . The use of ICU-related interven- tions and life-sustaining therapies did not differ across the four groups of patients. Severity of illness and organ dysfunction scores were similar between groups.
The Candida BSIs had the highest ICU and hospital mortality ( (Table 4) . When followed until hospital discharge, patients with Candida BSIs continued to have the highest mortality and hospital lengths of stay; however, the differences between Candida BSIs and other BSIs were diminished.
DISCUSSION
Analysis of the EPIC II database demonstrates that Candida BSIs continue to be associated with high morbidity and healthcare use in our ICU population.
The prevalence of 6.9 per 1000 patients in the EPIC II participating ICUs is in line with other published data (2, 4, 12, 30, 31) . The crude mortality rate of 42.6% is also consistent with previous reports. Interestingly, the higher mortality in patients with Candida BSIs, compared with other BSIs, is noted despite all patients with BSI having similar baseline demographics, severity of illness, and acute organ failure scores (32) . The EPIC II data also demonstrate that patients with Candida BSIs use extensive healthcare resources, especially in the ICU setting. Risk factors for candidemia in the ICU have been well described (25, 31, 33, 34) . Critical care clinicians are often asked to make therapeutic choices based on these risk factors with several predictive models being developed to identify patients in the ICU who are at high risk of invasive candidiasis (31, 35) . However, the clinical predictors in these rules are common in the EPIC II ICU population and seen with similar frequency in bacterial BSIs. Except for a modest difference in ICU length of stay at the time of the survey, we could find no difference in patients characteristic, ICU interventions, or severity of illness scores between Candida BSIs and other BSIs. This may help explain why a controlled trial of empirical antifungal therapy for ICU patients judged to be at high risk for invasive Candida infections had an invasive Candida rate of Ͻ10% and failed to show benefit with therapy (36) .
Early initiation of adequate antifungal therapy has been shown to improve survival in patients with candidemia (16, 37, 38) . Although recent guidelines recommend an echinocandin as the preferred class of agent in patients with moderately severe to severe illness Candida infections, only one trial comparing the echinocandin, anidulafungin, with fluconazole has shown greater efficacy than fluconazole with a trend toward improved survival (21) . The choice of therapy for invasive Candida infections is generally based on the severity of clinical illness and the most likely infecting species. Unlike other reports, C. albicans was by far the most frequent pathogen isolated in 70% of Candida BSIs. This may, in part, be explained by the regional differences in C. glabrata and other non-albicans species (3, 4, 14, 22, 23, 39) coupled with the predominance of participating ICUs in Europe (26) . Further prospective trials may be needed to support the recent IDSA recommendations, especially in regions where fluconazole susceptible species predominate and/or resources are limited.
An obvious strength of EPIC II study is the large, international and diverse population of ICU patients studied. EPIC II provides a snapshot of the current epidemiology, prescribing habits, and outcomes related to Candida BSIs in the adult ICU setting. As a result of the Ͼ14,000 patients in participating ICUs, the database includes a large cohort of critically ill patients with just over half believed to be infection and 5.4% of patients with BSIs. This allows for comparison of patients with Candida BSIs with patients with bacterial and mixed BSIs.
Restricting the analysis of potential Candida infection to only those patients with Candida BSIs substantially decreased the number of patients for analysis. However, it effectively eliminates confusion between patients who may be either colonized or infected (40) . Recent autopsy data suggest that essentially none of the Candida cultured from the airways of critically ill patients represents an invasive infection (41) . The clinical significance of funguria is unclear. The recent IDSA guidelines (17) state that culture from urine should be assessed in the context of the clinical setting and if no predisposing condition is uncovered, asymptomatic patients only warrant observation (42, 43) . There can also be difficulty distinguishing true invasive candidiasis from colonization by evaluating focal cultures such as abdominal drainage (40, 44) . Therefore, we chose to eliminate potential cofounding cultures and focused on patients with Candida BSIs. Although the prevalence of Candida BSI in EPIC II was 6.9 per 1000 population, this limited the number of patients available for this analysis. Still, we identified 99 patients with Candida BSIs and were able to compare risk factors and outcomes with the 420 patients with Grampositive BSIs and 264 patients with Gram-negative BSIs.
As a point prevalence study, the EPIC II study and this subpopulation analysis have important limitations. There were only 99 patients with Candida BSIs, limiting the power to detect significant differences between the more common bacterial BSIs. The database also lacks follow-up regarding the development of BSIs after the study observation date. Although investigators studied actual clinical practice, providing a snapshot of recent antifungal prescribing habits, EPIC II is an observational prevalence study with no interventions performed, limiting the evaluation of therapeutic choices. Additionally, the EPIC II database did not collect information on the onset of BSI and the timing of therapy. Because EPIC II was not funded, the voluntary nature of the study can be a potential source of bias. The high proportion of university hospitals could lead to a patient case-mix that is not representative for communitybased and other models of ICU care. As a prevalence study, EPIC II has the advantage of requiring a relatively limited data set while including a large number of patients; however, prevalence studies may overestimate the number of patients with diseases of long duration such as Candida and other BSIs.
CONCLUSION
As demonstrated by EPIC II, Candida BSI remains a significant problem in contemporary critically ill patients. Interestingly, C. albicans was the predominant organism and fluconazole remained the predominant antifungal agent used. Because Candida BSIs are associated with high ICU and hospital mortality rates and resource use, further studies are warranted to determine the best diagnostic means and treatment options for our critically ill patients with this severe infection.
